Hepatosplenic T-cell lymphoma
|Hepatosplenic T-cell lymphoma|
|Other names||hepatosplenic γδ T-cell lymphoma|
|Specialty||Hematology and oncology|
Hepatosplenic T-cell lymphoma is a rare and generally incurable form of lymphoma, except in the case of an Allogenic Stem Cell Transplant. Hepatosplenic T-cell lymphoma is a systemic neoplasm comprising medium-sized cytotoxic T-cells that show a significant sinusoidal infiltration in the liver, spleen, and bone marrow.
Signs and symptoms
Sites of involvement
The cell of origin for this disease is an immature cytotoxic T-cell clonally expressing the γδ T-cell receptor. This disease is seen more often in immunosuppressed solid organ transplant recipients, an association that has led to the hypothesis that long-term immune stimulation in the setting of immunosuppression is the causative agent.
Cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with the immunosuppressants azathioprine, infliximab and adalimumab. The majority of cases occurred in patients with inflammatory bowel disease. Adolescents and young adult males were the major cohort of cases. They presented with a very aggressive disease course and, with one exception, died of the lymphoma. The FDA has required changes to the labeling to inform users and clinicians of the issue.
Spleen and liver
While the bone marrow is commonly involved, the detection of the neoplastic infiltrate may be difficult due to diffuse, interstitial pattern. Immunohistochemistry can aid in the detection of this lymphoma.
|Positive||CD3, TCRδ1, TIA-1|
|Negative||CD4, CD5, CD8|
Clonal rearrangement of the γ gene of the T-cell receptor is the hallmark of this disease. A few cases have shown rearrangement of the T-cell receptor β gene. Isochromosome 7q has been observed in all cases described so far, sometimes in conjunction with other chromosomal abnormalities such as trisomy 8.
CHOP frequently induces remission initially, but has proven weak compared to treatments that integrate cytarabine with Hyper-CVAD being particularly effective, with chemo therapy only treatment most patients relapse and die within two years. Doxirubicin only treatment can make this disease much worse.Autologous bone marrow transplantation is currently being investigated in the treatment of hepatosplenic lymphoma. Allogeneic bone marrow transplant has been proven to attain remission for over five years and possibly cure hepatosplenic lymphoma with a number of patients surviving if they can make it to Allogenic transplant. 
- Elaine Sarkin Jaffe, Nancy Lee Harris, World Health Organization, International Agency for Research on Cancer, Harald Stein, J.W. Vardiman (2001). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumors. 3. Lyon: IARC Press. ISBN 92-832-2411-6.CS1 maint: multiple names: authors list (link)
- Rashidi, A.; Cashen, A. F. (2015). "Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma". Blood Cancer Journal. 5 (6): e318. doi:10.1038/bcj.2015.43. PMC 4648481. PMID 26047388.
- Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M (February 2007). "Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease". J. Pediatr. Gastroenterol. Nutr. 44 (2): 265–7. doi:10.1097/MPG.0b013e31802f6424. PMID 17255842.
- Farcet JP, Gaulard P, Marolleau JP, et al. (June 1990). "Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta". Blood. 75 (11): 2213–9. doi:10.1182/blood.V75.11.2213.2213. PMID 2140703.
- Cooke CB, Krenacs L, Stetler-Stevenson M, et al. (December 1996). "Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin". Blood. 88 (11): 4265–74. doi:10.1182/blood.V88.11.4265.4265. PMID 8943863.
- FDA Warning concerning azathioprine and Hepatosplenic T-cell lymphoma https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258794.htm
- Ross CW, Schnitzer B, Sheldon S, Braun DK, Hanson CA (September 1994). "Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen". Am. J. Clin. Pathol. 102 (3): 310–5. doi:10.1093/ajcp/102.3.310. PMID 8085554.
- Macon WR, Levy NB, Kurtin PJ, et al. (March 2001). "Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas". Am. J. Surg. Pathol. 25 (3): 285–96. doi:10.1097/00000478-200103000-00002. PMID 11224598.
- Alsohaibani, Fahad I.; Abdulla, Maheeba A.; Fagih, Mousa M. (2011). "Hepatosplenic T-Cell Lymphoma". Indian Journal of Hematology and Blood Transfusion. 27 (1): 39–42. doi:10.1007/s12288-010-0051-1. ISSN 0971-4502. PMC 3102508. PMID 22379294.
- Alonsozana EL, Stamberg J, Kumar D, et al. (August 1997). "Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma". Leukemia. 11 (8): 1367–72. doi:10.1038/sj.leu.2400742. PMID 9264394.